UnknownPhase 4

The POST-ACS Study

Potential Impact of Oral Semaglutide on Coronary Artery Disease Progression Following Acute Coronary Syndrome: The POST-ACS Study

Lead sponsor

Swansea Bay University Health Board

Asset

Semaglutide

GLP-1 agonist

Listed sites

Recruiting sites

Estimated enrollment

140

Study population

Cardiovascular disease, Prediabetes / glucose intolerance, Type 2 diabetes

Eligibility highlights

•HbA1c ≥5.7%

Primary endpoint

•Compare the regression of vulnerable coronary plaque (necrotic core) assessed

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05322200

Org study ID275165

Timeline

Milestones

Study first posted2022-04-11actual

Study start2022-08-31actual

Last update posted2022-10-27actual

Primary completion2024-04-28estimated

Study completion2024-08-01estimated

Assets

Investigational agents

Semaglutide

Who this study enrolls

Cardiovascular diseasePrediabetes / glucose intoleranceType 2 diabetes

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•HbA1c > 5.7% (39 mmol/mol)

•Patients presented with a clinical diagnosis of ACS comprising detection of a rise and/or fall of cardiac troponin (cTn) with at least one value above the 99th percentile and with at least one of the following:

1. Symptoms of acute myocardial ischemia;

2. New ischemic electrocardiographic (ECG) changes (ST-T wave changes or new LBBB);

3. Development of pathological Q waves;

4. Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality in a pattern consistent with an ischemic aetiology;

5. Identification of a coronary thrombus by angiography including intracoronary imaging or by autopsy

Exclusion criteria

•Type 1 DM

•Left ventricular ejection fraction <40%

•Heart failure classified as being in New York Heart Association (NYHA) Class III-IV.

•Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to screening or in the period between screening and randomisation.

•History of renal insufficiency with estimated glomerular filtration rate <30mL/min/1.73m2

•A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

•History of treatment with GLP-1 within 90 days before screening

•Current use of SGLT-2 inhibitors within 30 days of screening

•Known or suspected hypersensitivity to Semaglutide or related products.

•Female who is pregnant, breastfeeding or intends to become pregnant, or is of child-bearing potential and not using a highly effective contraceptive method.

•Current enrolment in any other clinical trial within 30 days from screening

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiometabolic biomarkers

Other (unclassified)

Cardiometabolic biomarkers

4 endpoints

Primary/protocol endpoint/low confidence

Compare the regression of vulnerable coronary plaque (necrotic core) assessed using histologically validated "Plaque Maps" derived from CT Coronary angiography in patients with raised HbA1c admitted with ACS and treated with oral Semaglutide or placebo.

Time frame:12 months

change from baseline, improvement

Secondary/protocol endpoint

-Evaluate the effect of oral Semaglutide on atherosclerotic plaque burden.

Time frame:12 months

percent change from baseline, improvement

Secondary/protocol endpoint/low confidence

Evaluate the effect of oral Semaglutide on levels of biomarkers of inflammation.

Time frame:12 months

change from baseline, improvement

Secondary/protocol endpoint

-Evaluate any potential effect of oral Semaglutide on arterial stiffness

Time frame:12 months

change from baseline, improvement

Other (unclassified)

1 endpoint

Secondary/protocol endpoint/low confidence

Evaluate the effect of oral Semaglutide on levels of biomarkers of oxidative stress.

Time frame:12 months

change from baseline, improvement

componentsox ldl, taos, tbars

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.